2 Information about pembrolizumab with carboplatin and paclitaxel

2 Information about pembrolizumab with carboplatin and paclitaxel

Marketing authorisation indication

Pembrolizumab (Keytruda, Merck Sharp & Dohme), 'in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of metastatic squamous NSCLC in adults'.

Dosage in the marketing authorisation

200 mg every 3 weeks by intravenous infusion (when part of combination therapy). The summary of product characteristics recommends treatment with pembrolizumab until disease progression or unacceptable toxicity.

Price

£2,630 per 100‑mg/4‑ml vial (BNF online, accessed April 2019).

The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)